Bristol-Myers Squibb (BMY) Tops Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Bristol-Myers Squibb (BMY) Tops Q3 EPS by 6c

TCR2 Therapeutics (TCRR) Collaborates with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo and Yervoy in Mesothelin-Expressing Solid Tumors

October 25, 2021 6:47 AM EDT

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate gavo-cel in combination with Opdivo® (nivolumab) and Yervoy® (ipilimumab) in its planned Phase 2 clinical trial in treatment refractory mesothelin-expressing solid tumors. The primary objective of the Phase 2... More